Heart safety check for cancer drug selpercatinib
NCT ID NCT05630274
First seen Jun 25, 2026 · Last updated Jun 26, 2026 · Updated 1 time
Summary
This completed Phase 1 study looked at whether a single dose of selpercatinib, a cancer drug, changes the heart's electrical activity (QT interval) in 32 healthy adults. Participants received selpercatinib, a placebo, or a control drug (moxifloxacin) in a crossover design. The main goal was to measure any heart rhythm effects to ensure the drug's safety for future use.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Selpercatinib (also known as LOXO-292)
What this could lead to
If successful, this study will confirm that selpercatinib does not cause dangerous heart rhythm changes, supporting its safe use in patients.
What could go wrong
This is a small, early-phase study in healthy volunteers, not patients. Heart effects seen here may differ in sicker populations or with long-term use.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Celerion
Tempe, Arizona, 85283, United States